Search results for: tocilizumab

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

Vanessa Caceres | January 25, 2021

In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.

Case Report: A Non-Tuberculous Mycobacterial Infection

Bradley Bohman, MD, & Jawad Bilal, MBBS | January 20, 2021

Tumor necrosis factor-α inhibitors (TNFi’s) have emerged as an integral part of therapeutic strategies for several rheumatic diseases. TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). It also plays a central role in the immune response to mycobacterial infection. Many biologic agents, particularly…

The State of Clinical Research in Vasculitis: 2021

Shubhasree Banerjee, MD, & Peter A. Merkel, MD, MPH | January 19, 2021

It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

FDA Provides 2020 Rheumatology Drug Update

Susan Bernstein | December 17, 2020

Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.

Evaluation & Treatment of Systemic Sclerosis-ILD in the New Decade

Thomas R. Collins | December 17, 2020

ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.

The 2020 ACR Review Course: Key Issues Rheumatologists Face

Jason Liebowitz, MD, FACR | December 17, 2020

The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.

Medicare’s Most Favored Nation Is My Least Favorite Notion!

Angus B. Worthing, MD | December 8, 2020

In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…

Single-Cell Technologies: A Path for New Insights

Lara C. Pullen, PhD | December 7, 2020

This ACR Convergence session discussed how recent advances in single-cell technologies are being used in rheumatic disease research.

10 Clinical Insights from Rheumatology Top Secrets & Pearls

Vanessa Caceres | December 7, 2020

In this ACR Convergence session, Jason R. Kolfenbach, MD, & John H. Stone, MD, MPH, shared clinical insights about rheumatic diseases.

Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA

Vanessa Caceres | November 24, 2020

ACR CONVERGENCE 2020—Patients with rheumatoid arthritis (RA) and concurrent liver disease or interstitial lung disease (ILD), or with treatment-refractory RA, pose treatment challenges, said panelists in the ACR Convergence 2020 session, How I Treat Difficult RA. Each panelist discussed a difficult case and raised big-picture questions on how to best treat patients facing each challenge….